Novartis Menveo Vaccine Shows Superior Immune Response Against Four Types of Meningitis Disease in Pivotal Phase III Trial
* First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra* * Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood * More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo
* First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*
* Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood
* More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo
BASEL, Switzerland, May 6, 2008 - New Phase III data for
Menveo® (MenACWY-CRM) show that the vaccine produced a greater
immune response against meningococcal serogroups A, C, W-135 and Y
in adolescents 11-18 years of age compared to Menactra®.
Infection with any of these four vaccine-preventable serogroups can
lead to bacterial meningitis, an infection of the membrane around
the brain and spinal cord, or sepsis, a serious infection of the
Results of this first head-to-head trial of Menveo compared to Menactra, show that
adolescents who were immunized with Menveo generated higher levels of antibodies
against all four serogroups2.
Notably for serogroup Y, among adolescents with low levels of immunity at the time of
vaccination, 81% of subjects receiving Menveo generated a protective immune response vs.
54% with Menactra2, as measured by the hSBA assay. Serogroup Y causes approximately
39% of meningococcal disease cases in the US3.
“To protect children against all major serogroups of meningococcal disease, we need
vaccines that provide broad coverage and that can be used in all at-risk age groups,” said
Keith S. Reisinger, MD, MPH, Medical Director, Primary Physicians Research, Inc.
Pittsburgh, PA. ”These data are encouraging because they show that Menveo may provide
greater protection for the more than 8 million infants and adolescents in the US against
these four vaccine-preventable serogroups than the currently available vaccine.”
Menveo is an investigational quadrivalent meningococcal conjugate vaccine in Phase III
clinical development by Novartis Vaccines. The data were presented at a late-breaker
platform session on May 5 during the 2008 Pediatric Academic Societies (PAS) Annual
Meeting in Honolulu, Hawaii.
Meningococcal disease, a leading cause of bacterial meningitis, is a rare but contagious and
potentially life-threatening infection. Infants and adolescents have the highest rates of
disease4a, which can be fatal. Each year approximately 1,400 to 2,800 cases of disease
occur in the US4b, and about 10-14 percent of patients die4c. The currently available
vaccines are not licensed for use in infants, in whom the highest rates of meningococcal
disease are observed. Phase II data published in the January 9, 2008, issue of the Journal of
the American Medical Association demonstrated Menveo to be the first meningococcal
vaccine to produce a strong immune response in infants5.
The US Centers for Disease Control and Prevention (CDC) recommends routine
immunization with a quadrivalent meningococcal conjugate vaccine for all adolescents 11-
18 years of age, college freshmen living in dormitories and people in other high risk groups
who are two to ten or 19 to 55 years of age6,7.
“The patient need for vaccines for meningococcal disease remains substantial. We appear
to be quickly realizing our goal of providing broad coverage against all serogroups of
meningococcal disease across all age groups,” said Joerg Reinhardt, CEO of Novartis
Vaccines and Diagnostics. “Given the broad range of age groups this vaccine is expected to
protect, Menveo could truly fulfill an unmet need in the meningitis vaccine market.”
This Phase III trial involved more than 2,100 11-18 year olds who received a single
vaccination with either Menveo or Menactra. One month after vaccination, geometric
mean titers (a measure of immune response) for Menveo vs. Menactra were: serogroup A,
29 vs. 18; serogroup C, 59 vs. 47; serogroup W-135, 87 vs. 44; and serogroup Y, 51 vs.
18. Additionally, the percentage of participants who achieved a protective immune
response, determined by a human serum bactericidal antibody titer (hSBA) > 1:8, with
Menveo vs. Menactra was: serogroup A, 75% vs. 67%; serogroup C, 84% vs. 84%;
serogroup W-135, 96% vs 88%; and serogroup Y, 88% vs. 69%. Similar results were
seen in the large subset of sero-negative participants, who are the participants without any
natural immunity to the bacteria before vaccination. The hSBA assay measures the body’s
protective immune response to the meningococcus based on the ability of antibodies to kill
These data build on previous studies that demonstrated Menveo generates a strong
protective immune response against these four vaccine-preventable serogroups in people
across age groups from infancy to adulthood. Novartis expects to submit a Biologics
License Application (BLA) to the US Food and Drug Administration later this year.
Menveo is currently in multiple Phase III clinical trials involving infants, young children,
adolescents and adults. The vaccine is based on the same technology Novartis pioneered to
produce Menjugate®, a meningococcal serogroup C conjugate vaccine approved outside
the US since 2000 for use in individuals from two months of age through adulthood.
Novartis is a global leader in providing vaccines to protect against the deadly
meningococcal disease. In addition to developing Menveo, Novartis has already distributed
more than 26 million doses of Menjugate around the world and produced MenZB®, a
vaccine against a strain of meningococcus B specific to a recent outbreak in New Zealand.
Novartis is also developing a recombinant vaccine to provide broad coverage against
multiple strains of serogroup B, for which no vaccine is currently available.
About meningococcal disease, a leading cause of bacterial meningitis
Meningococcal disease can manifest as bacterial meningitis – an infection of the
membranes around the brain and spinal cord – or sepsis, a bloodstream infection. It is
caused by the bacterium Neisseria meningitidis (N. meningitidis). The symptoms – which
can include sudden onset of fever, rash, headache, and stiff neck – can progress rapidly.
Even with early and appropriate treatment, some cases are fatal4b, typically within 24-48
hours8. For those who survive, as many as 19 percent suffer serious long-term
consequences such as deafness, neurological damage or limb loss4d.
The foregoing release contains forward-looking statements that can be identified by
terminology such as “may”, “expects”, and “encouraging”, “potentially”, “can be”,
“goal”, “expected”, or similar expressions, or by express or implied discussions regarding
potential future regulatory filings or approvals for, or potential future sales of, Menveo or
other vaccines currently in development by Novartis. Such forward-looking statements
reflect the current views of Novartis regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results with Menveo
to be materially different from any future results, performance or achievements expressed
or implied by such statements. There can be no guarantee that Menveo or any other
vaccine currently in development by Novartis will be submitted or approved for any
indications in any market. Nor can there be any guarantee that Menveo or any other
vaccine, if approved, will achieve any particular levels of sales. In particular, management’s
expectations regarding Menveo could be affected by, among other things, unexpected
clinical trial results, including unexpected new clinical data and unexpected additional
analysis of existing clinical data; unexpected regulatory actions or delays or government
regulation generally; Novartis’ ability to obtain or maintain patent or other proprietary
intellectual property protection; competition in general; government, industry and general
public pricing pressures, and other risks and factors referred to in Novartis AG’s Form 20-
F on file with the U.S. Securities and Exchange Commission. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those anticipated, believed, estimated or expected.
Novartis is providing the information in this press release as of this date and does not
undertake any obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
Novartis Vaccines and Diagnostics is a division of Novartis focused on the development of
preventive treatments. The division has two businesses: Novartis Vaccines and Chiron.
Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest
supplier of flu vaccines in the US. The division's products include influenza,
meningococcal, pediatric and travel vaccines. Chiron, the blood testing and molecular
diagnostics business, is dedicated to preventing the spread of infectious diseases through
the development of novel blood-screening tools that protect the world's blood supply.
Novartis AG provides healthcare solutions that address the evolving needs of patients and
societies. Focused on growth areas in healthcare, Novartis offers a diversified portfolio to
best meet these needs: innovative medicines, cost-saving generic pharmaceuticals,
preventive vaccines and diagnostic tools, and consumer health products. Novartis is the
only company with leading positions in these areas. In 2007, the Group’s continuing
operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net
income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities
throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies
employ approximately 98,000 full-time associates and operate in over 140 countries
around the world. For more information, please visit http://www.novartis.com.
1. Novartis Vaccines and Diagnostics Earnings Presentations. Growth Through Innovation. January 17,
2. Jackson L, et al. A Phase III study comparing the safety and immunogenicity of a novel qualdrivalent
meningococcal conjugate vaccine, MenACWY-CRM, with the licensed MCV4, Menactra® in adolescents.
Abstract # 5628.8, 2008 Pediatric Academic Society Annual Meeting, Honolulu, HI.
3. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging
Infections Program Network, Neisseria meningitidis, 2006.
Available at: http://www.cdc.gov/ncidod/dbmd/abcs/survreports/mening06.pdf
4. U.S. Centers for Disease Control. Fact Sheet: Meningococcal Disease and Meningococcal Vaccines (April
25, 2006). Available at: http://www.cdc.gov/vaccines/vpd-vac/mening/vac-mening-fs.htm
5. Snape, MD et al. Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants: A
Randomized Controlled Trial. Journal of the American Medical Association. 2008; 299(2):173-184
6. Centers for Disease Control and Prevention. Revised recommendations of the Advisory Committee on
Immunization Practices to vaccinate all persons aged 11--18 years with meningococcal conjugate vaccine.
7. Centers for Disease Control and Prevention. Notice to readers: Recommendations from the Advisory
committee on Immunization Practices for use of quadrivalent meningococcal conjugate vaccine (MCV4) in
children aged 2-10 years at increased risk for invasive meningococcal disease. MMWR. 2007;56(48):1265-
8. WHO. Meningococcal meningitis Fact sheet #141. May 2003.
# # #
Novartis Media Relations
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 618 7748 (mobile)
Novartis Vaccines and Diagnostics
+1 (617) 871 4281 (direct)
+1 (617) 803 4359 (mobile)
Novartis Investor Relations
Ruth Metzler-Arnold +41 61 324 9980
Katharina Ambuehl +41 61 324 5316 North America Office
Pierre-Michel Bringer +41 61 324 1065 Richard Jarvis +1 212 830 2433
John Gilardi +41 61 324 3018 Jill Pozarek +1 212 830 2445
Thomas Hungerbuehler +41 61 324 8425 Edwin Valeriano +1 212 830 2456
Isabella Zinck +41 61 324 7188
Central phone no: +41 61 324 7944
Fax no: +41 61 324 8444 Fax no: +1 212 830 2405
e-mail: firstname.lastname@example.org e-mail: email@example.com
* Menactra is a registered trademark of Sanofi Pasteur.
Posted: May 2008